In the Claims

Please amend the claims of the above-identified application as follows:

Claims 1 – 18 **(cancelled)**

19. **(currently amended)** A pharmaceutical composition for the treatment of appetency disorders containing a CB_1 receptor antagonist and a regulator of metabolic functions together with a pharmaceutical excipient.

20. **(previously amended)** A pharmaceutical composition according to claim 19 wherein said regulator of metabolic functions is a β_3-agonist.

21. **(previously amended)** A pharmaceutical composition according to claim 20 wherein the CB_1 receptor antagonist is a compound of the formula



(II)

in which:

- R_1 is hydrogen, a fluorine, a hydroxyl, a $(C_1$-$C_5)$alkoxy, a $(C_1$-$C_5)$alkylthio, a hydroxy$(C_1$-$C_5)$alkoxy, a group $-NR_{10}R_{11}$, a cyano, a $(C_1$-$C_5)$alkylsulfonyl or a $(C_1$-$C_5)$alkylsulfinyl;
- R_2 and R_3 are a $(C_1$-$C_4)$alkyl or, together with the nitrogen atom to which they are bonded, form a saturated or unsaturated 5- to 10-membered heterocyclic radical which is unsubstituted or monosubstituted or polysubstituted by a $(C_1$-$C_3)$alkyl or by a $(C_1$-$C_3)$alkoxy;
- R_4, R_5, R_6, R_7, R_8 and R_9 are each independently hydrogen, a halogen or a trifluoromethyl, and if R_1 is a fluorine, R_4, R_5, R_6, R_7, R_8 and/or R_9 can also be a fluoromethyl, with the proviso that at least one of the substituents R_4 or R_7 is other than hydrogen;
- R_{10} and R_{11} are each independently hydrogen or a $(C_1$-$C_5)$alkyl, or R_{10} and R_{11}, together with the nitrogen atom to which they are bonded, form a heterocyclic radical selected from pyrrolidin-1-

yl, piperidin-1-yl, morpholin-4-yl and piperazin-1-yl, which is unsubstituted or substituted by a $(C_1\text{-}C_4)$alkyl,

one of its salts or one of their solvates.

22. **(previously amended)** A pharmaceutical composition according to claim 21 wherein the CB_1 receptor antagonist is N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide, one of its pharmaceutically acceptable salts or one of their solvates.

23. **(previously amended)** A pharmaceutical composition according to claim 21 wherein the β_3-agonist is a compound of the formula



(III)

in which:

- X is hydrogen, a halogen, a trifluoromethyl or a $(C_1\text{-}C_4)$alkyl;
- R is hydrogen or a methyl which is unsubstituted or substituted by a carboxyl or an alkoxycarbonyl in which the alkoxy is $(C_1\text{-}C_6)$,

or one of its pharmaceutically acceptable salts.

24. **(previously amended)** A pharmaceutical composition according to claim 21 wherein the β_3-agonist is a compound of the formula



(IV)

in which:

- n is 1, 2 or 3;
- A is a benzofuran-2-yl or a phenyl which is unsubstituted or substituted by one or two halogen atoms or by a $(C_1\text{-}C_4)$alkyl or a trifluoromethyl;

- R′ is:
- hydrogen;
- a (C_1-C_6)alkyl;
- a functional group selected from the following groups: hydroxyl; (C_1-C_6)alkoxy; (C_2-C_6)alkenyloxy; (C_2-C_6)alkynyloxy; (C_3-C_8)cycloalkoxy; (C_3-C_8)cycloalkyl(C_1-C_6)alkoxy; benzyloxy; phenoxy; mercapto; (C_1-C_6)alkylthio; (C_2-C_6)alkenylthio; (C_2-C_6)alkynylthio; (C_3-C_8)cycloalkylthio; (C_3-C_8)cycloalkyl(C_1-C_6)alkylthio; benzylthio; phenylthio; (C_1-C_6)alkylsulfinyl; (C_2-C_6)alkenylsulfinyl; (C_2-C_6)alkynylsulfinyl; (C_3-C_8)cycloalkylsulfinyl; (C_3-C_8)cycloalkyl(C_1-C_6)alkylsulfinyl; benzylsulfinyl; phenylsulfinyl; (C_1-C_6)alkylsulfonyl; (C_2-C_6)alkenylsulfonyl; (C_2-C_6)alkynylsulfonyl; (C_3-C_8)cycloalkylsulfonyl; (C_3-C_8)-cycloalkyl(C_1-C_6)alkylsulfonyl; benzylsulfonyl; phenylsulfonyl; cyano; nitro; amino which is unsubstituted or substituted by one or two identical or different radicals selected from (C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, (C_3-C_8)cycloalkyl, (C_3-C_8)cycloalkyl(C_1-C_6)alkyl, benzyl and phenyl groups; carboxyl; alkoxycarbonyl in which the alkoxy is (C_1-C_6); (C_2-C_6)alkenyloxycarbonyl; (C_2-C_6)alkynyloxycarbonyl; (C_3-C_8)cycloalkoxycarbonyl; (C_3-C_8)cycloalkyl(C_1-C_6)alkoxycarbonyl; benzyloxycarbonyl; phenoxycarbonyl; and carbamoyl which is unsubstituted or substituted on the amino group by one or two identical or different radicals selected from (C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, (C_3-C_8)cycloalkyl, (C_3-C_8)cycloalkyl(C_1-C_6)alkyl, benzyl and phenyl groups;
- a group R″′ selected from the following groups: (C_1-C_6)alkyl substituted by a functional group; (C_2-C_6)alkenyl substituted by a functional group; (C_2-C_6)alkynyl substituted by a functional group; phenyl(C_1-C_6)alkyl substituted on the phenyl by a (C_1-C_6)alkyl or by a functional group; phenyl(C_2-C_6)alkenyl substituted on the phenyl by a (C_1-C_6)alkyl or by a functional group; phenyl(C_2-C_6)alkynyl substituted on the phenyl by a (C_1-C_6)alkyl or by a functional group; benzyl substituted on the phenyl by a (C_1-C_6)alkyl or by a functional group; and phenyl which is unsubstituted or substituted by a (C_1-C_6)alkyl or by a functional group, the functional group being as defined above;
- a group O-R″′, S-R″′, SO-R″′ or SO_2-R″′, in which R″′ is as defined above;

- a group NR'''R°, in which R''' is as defined above and R° is hydrogen or is as defined above for R''', or R''' and R°, together with the nitrogen to which they are bonded, form a group selected from pyrrolidino, piperidino and morpholino groups;
- a group COOR''' or a group CO-SR''', in which R''' is as defined above;
- a group CONR'''R°, in which R''' is as defined above and R° is hydrogen or is as defined above for R''', or R''' and R°, together with the nitrogen to which they are bonded, form a group selected from pyrrolidino, piperidino and morpholino groups;
- a group $SO_2NR'''R°$, in which R''' is as defined above and R° is hydrogen or is as defined above for R''', or R''' and R°, together with the nitrogen to which they are bonded, form a group selected from pyrrolidino, piperidino and morpholino groups;

- R'' is hydrogen; a halogen; a (C_1-C_6)alkyl; a functional group as defined above; a group OR''', R''' being as defined above; a group COOR''', R''' being as defined above; or a group CONR'''R°, in which R''' is as defined above and R° is hydrogen or is as defined above for R''', or R''' and R°, together with the nitrogen to which they are bonded, form a group selected from pyrrolidino, piperidino and morpholino groups;
- W is a direct bond or an oxygen atom;
- X' is hydrogen, a (C_1-C_6)alkyl or a (C_1-C_6)alkylcarbonyl;
- Y is hydrogen or a group A'-CH(OH)-CH_2-, A' being identical to A but other than benzofuran-2-yl; or
- X' and Y, taken together, form a methylene group optionally substituted by an alkoxycarbonyl in which the alkoxy is (C_1-C_6); an ethylene group optionally substituted by an oxo group; or a 1,3-propylene group;
- Z is hydrogen or a (C_1-C_6)alkyl,

or one of its pharmaceutically acceptable salts.

25. **(previously amended)** A pharmaceutical composition according to claim 21 wherein the β_3-agonist is a compound of the formula



(V)

in which:

- E is hydrogen, a $(C_1$-$C_4)$alkyl, a $(C_1$-$C_4)$alkoxy, a phenyl, a nitro, a halogen atom or a trifluoromethyl;
- L is hydrogen, a $(C_1$-$C_4)$alkyl, a $(C_1$-$C_4)$alkoxy, a phenyl, a nitro or a halogen atom; or E and L together are a group -CH=CH-CH=CH- or $-CH_2-CH_2-CH_2-CH_2-$; and
- G is hydrogen, a chlorine atom, a hydroxyl or a group OG', in which G' is a $(C_1$-$C_4)$alkyl which is unsubstituted or substituted by a hydroxyl, $(C_1$-$C_4)$alkoxy, $(C_1$-$C_4)$alkoxycarbonyl, carboxyl or $(C_3$-$C_7)$cycloalkyl; a $(C_3$-$C_7)$cycloalkyl; or a $(C_2$-$C_4)$alkanoyl,

or one of its pharmaceutically acceptable salts.

26. **(previously amended)** A pharmaceutical composition according to claim 23 wherein the β_3 agonist is N-[(2S)-7-ethoxycarbonylmethoxy-1,2,3,4-tetrahydronaphth-2-yl]-(2R)-2-(3-chloro-phenyl)-2-hydroxyethanamine or one of its pharmaceutically acceptable salts.

27. **(previously amended)** A pharmaceutical composition according to claim 23 containing from 0.5 to 600 mg of CB_1 receptor antagonist and from 0.5 to 600 mg of β_3-agonist.

28. **(original)** A pharmaceutical composition according to claim 27 containing from 1 to 400 mg of CB_1 receptor antagonist and from 2 to 400 mg of β_3-agonist.

29. **(original)** A pharmaceutical composition according to claim 28 containing from 2 to 200 mg of CB_1 receptor antagonist and from 10 to 250 mg of β_3-agonist.

Claims 30 – 38 **(cancelled)**

39. **(previously added)** A pharmaceutical composition according to claim 26 wherein the CB_1 antagonist is N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide or one of its pharmaceutically acceptable salts or one of their solvates.